Home Companies Spyre Therapeutics COMPANY
Clinical Phase 2
6 open jobs · last seen Oct 23, 2026 · 11 sources
Keywords: immunology Ulcerative Colitis Inflammatory Bowel Diseases Colitis Hidradenitis Suppurativa Rheumatoid Arthritis Psoriatic Arthritis Axial Spondyloarthritis Rheumatic Diseases Rheumatic Joint Disease PsA (Psoriatic Arthritis) AxSpA Rheumatologic Disease SPY001 SPY002 SPY003 SPY002-072 SPY002-091 SPY072 SPY003-207 SPY001-001 Show all 21 keywords
Location: Waltham, MA · source · Oct 14, 2026
Profile checked Oct 10, 2026
Hiring Title Location (from posting) Employer posted First seen Senior Director, Biostatistics US- Remote Oct 5, 2026 Oct 11, 2026 Senior Scientist, Translational Science US- Remote Oct 1, 2026 Oct 11, 2026 Director, Drug Safety Physician US- Remote Sep 30, 2026 Oct 11, 2026 Senior Director, Drug Safety and Pharmacovigilance Operations US- Remote Sep 25, 2026 Oct 11, 2026 Associate Director, Clinical Supply Chain US- Remote Sep 23, 2026 Oct 11, 2026
See all 6 jobs
At a glance HQ Waltham, MA source Stage Clinical Phase 2 Latest trial Phase 2: A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial) (2026-09) source Timeline Oct 6, 2026 Raise Follow-on offering: $350M (total, as published), announced Oct 6, 2026. Source: company release on GlobeNewswire. source ↗ 2026-09 Trial start Phase 2: A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial) source ↗ Jun 8, 2026 Trial start Phase 2: Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD source ↗ Apr 16, 2026 Raise Follow-on offering: $463.5M (total, as published), announced Apr 16, 2026. Source: company release on GlobeNewswire. source ↗ Oct 15, 2025 Raise Follow-on offering: $316.2M (total, as published), announced Oct 15, 2025. Source: company release on GlobeNewswire. source ↗ Aug 21, 2025 Trial start Phase 2: A Study of SPY072 in Rheumatic Disease source ↗ May 27, 2025 Trial start Phase 2: A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis source ↗ Mar 10, 2025 Trial start Phase 1: A Study of SPY003-207 in Healthy Volunteers source ↗ Nov 26, 2024 Trial start Phase 1: A Study of SPY002-091 in Healthy Volunteers source ↗ Nov 18, 2024 Trial start Phase 1: A Study of SPY002-072 in Healthy Volunteers source ↗ Jun 6, 2024 Trial start Phase 1: A Study of SPY001-001 in Healthy Volunteers source ↗ Upcoming milestones Oct 31, 2026 (ESTIMATED) · Phase 2 · A Study of SPY072 in Rheumatic Disease · NCT07148414 Nov 18, 2026 (ESTIMATED) · Phase 1 · A Study of SPY003-207 in Healthy Volunteers · NCT06873724 2027-06 (ESTIMATED) · Phase 2 · A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis · NCT07012395 2027-10 (ESTIMATED) · Phase 2 · A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial) · NCT07766005 Mar 2, 2029 (ESTIMATED) · Phase 2 · Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD · NCT07652294 Estimated primary completion per ClinicalTrials.gov. Dates move.
Funding Raised: $1.1B. Last 2 years.
Oct 6, 2026 Follow-on offering: $350M (total, as published), announced Oct 6, 2026. Source: company release on GlobeNewswire. source ↗ Apr 16, 2026 Follow-on offering: $463.5M (total, as published), announced Apr 16, 2026. Source: company release on GlobeNewswire. source ↗ Oct 15, 2025 Follow-on offering: $316.2M (total, as published), announced Oct 15, 2025. Source: company release on GlobeNewswire. source ↗ Clinical trials (lead sponsor) 8 Record Title Phase Status Start Primary completion NCT07012395 A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis Phase 2 Recruiting May 27, 2025 2027-06 (estimated) NCT07652294 Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD Phase 2 Enrolling by invitation Jun 8, 2026 Mar 2, 2029 (estimated) NCT06672718 A Study of SPY002-091 in Healthy Volunteers Phase 1 Completed Nov 26, 2024 Aug 19, 2026 (actual) NCT06622070 A Study of SPY002-072 in Healthy Volunteers Phase 1 Completed Nov 18, 2024 Jul 28, 2026 (actual) NCT07766005 A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial) Phase 2 Not yet recruiting 2026-09 2027-10 (estimated) NCT07148414 A Study of SPY072 in Rheumatic Disease Phase 2 Active, not recruiting Aug 21, 2025 Oct 31, 2026 (estimated) NCT06873724 A Study of SPY003-207 in Healthy Volunteers Phase 1 Active, not recruiting Mar 10, 2025 Nov 18, 2026 (estimated) NCT06448247 A Study of SPY001-001 in Healthy Volunteers Phase 1 Completed Jun 6, 2024 Mar 10, 2026 (actual)
Open jobs 6 Title Location (from posting, not HQ) Employer posted First seen Level Senior Director, Biostatistics US- Remote Oct 5, 2026 Oct 11, 2026 Senior Description Senior Scientist, Translational Science US- Remote Oct 1, 2026 Oct 11, 2026 Senior Description Director, Drug Safety Physician US- Remote Sep 30, 2026 Oct 11, 2026 Senior Description Senior Director, Drug Safety and Pharmacovigilance Operations US- Remote Sep 25, 2026 Oct 11, 2026 Senior Description Associate Director, Clinical Supply Chain US- Remote Sep 23, 2026 Oct 11, 2026 Senior Description Vice President, Clinical Development US- Remote Jul 21, 2026 Oct 11, 2026 Executive Description
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
Connect See your connections at Spyre Therapeutics on LinkedIn (search by name, results not checked) LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.
LinkedIn page linked from the company's own site: source · seen 2026-10-18
